M&A

Merck acquires Cubist Pharmaceuticals for $9.5bn

Posted on 08 December 2014

Tags: , , ,

Merck and Cubist Pharmaceuticals have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubist’s average stock price for the most recent five trading days.

Unanimously approved by the boards of directors of both companies, the transaction has an equity valuation of $8.4 billion and will also include $1.1 billion in net debt (based on projected cash balances) and other considerations for a total transaction value of approximately $9.5 billion.

Cubist complements Merck’s strategy and the global initiative Merck launched last year, particularly in the area of sharpening its commercial focus on key therapeutic areas that have the potential to deliver the greatest return on investment.

With the company’s long-standing leadership in anti-infectives as well as its customer-focused operating model, Merck identified the hospital acute care segment as one of the company’s key priority areas in which it believes it can have the greatest impact in addressing significant unmet medical needs while delivering the greatest value to customers and society.

For further deal information visit Current Agreements (subscription required)

Related

Report:   Top 50 Big Pharma Partnering and M&A Deal Trends

Report:   Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

Print Friendly, PDF & Email

Leave a Reply